Navigation Links
BioMarin to Present at the Cowen and Company 29th Annual Health Care Conference
Date:3/10/2009

NOVATO, Calif., March 10 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey H. Cooper, Senior Vice President and Chief Financial Officer of BioMarin, will present a company update at the Cowen and Company 29th Annual Health Care Conference in Boston on Tuesday, March 17th, 2009 at 9:30 a.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin(R), Naglazyme(R) and Kuvan(R) are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

    Contacts:

    Investors                                Media
    Eugenia Shen                             Susan Berg
    BioMarin Pharmaceutical Inc.             BioMarin Pharmaceutical Inc.
    (415) 506-6570                           (415) 506-6594


'/>"/>
SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioMarin to Present at the Barclays Capital Global Healthcare Conference
2. BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
3. BioMarin Supports Observance of Rare Disease Day February 28
4. BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
5. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
6. BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
7. BioMarin to Present at the Lehman Brothers Global Healthcare Conference
8. BioMarin to Present at the Cowen and Company 28th Annual Healthcare Conference
9. BioMarin to Host Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast on Tuesday, February 26 at 5:00 p.m. ET (23:00 CET)
10. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
11. BioMarin Re-Acquires Rights to Kuvan in Canada From Merck Serono
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... The RIDER Institute announces an IndieGoGo ... broad-spectrum antiviral therapeutics. DRACOs have proven effective against all 18 viruses tested in ... http://igg.me/at/EndTheVirus and runs for 60 days, we are raising new funding ...
(Date:5/4/2016)... ... May 04, 2016 , ... a2z, Inc. ... Society™ and Canadian Association for Enterostomal Therapy (CAET) will be utilizing powerful and ... tools to attendees and exhibitors for the 2016 WOCN Society & CAET Joint ...
(Date:5/4/2016)... ... , ... May kicked off with Melanoma Monday , a multi-agency effort ... Turner is encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, ... now and in the future. , The dermatology-specific awareness month ends with “Don’t Fry ...
(Date:5/4/2016)... ... 04, 2016 , ... Recognizing that lifestyle medicine is essential to health and ... tapped David Katz, MD, MPH, president of the American College of Lifestyle Medicine, as ... is especially gratifying,” said Katz. “There is so much opportunity to add years to ...
(Date:5/4/2016)... TX (PRWEB) , ... May 04, 2016 , ... ... Nightstick all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in models ... Las Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... , May 4, 2016 BiondVax Pharmaceuticals ... Dr. Ron Babecoff , will be attending the Joseph ... . On Thursday, May 5, Dr. Babecoff ... presented by Joseph Gunner & Co, taking place ... presentation that Dr. Babecoff will be using is downloadable from ...
(Date:5/4/2016)... May 4, 2016 Valeritas Holdings, ... an alternative public offering (APO). This was accomplished via ... Valeritas, Inc. and a private placement of approximately 5 ... per share. Under the terms of the ... Valeritas Holdings, Inc. will trade on the OTC Markets ...
(Date:5/4/2016)... 4, 2016 Research ... "Global Actinic Keratosis Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Competitive Landscape Highlights 2016, provides comprehensive insights ... epidemiology, Actinic Keratosis market valuations and forecast, ...
Breaking Medicine Technology: